Product Information
Paprotrain is a potent inhibitor of epidermal growth factor receptor (EGFR) that binds to the EGFR and inhibits its activity. It has been shown to inhibit the growth of cancer cells resistant to other EGFR inhibitors, such as gefitinib and erlotinib. Paprotrain also inhibits tumour cell viability in vitro by inducing apoptosis. In addition, it has been shown to inhibit the phosphorylation of kinesin and actin filaments, which are involved in cell motility and proliferation. This drug has prognostic value in prostate and breast cancer because it is associated with a poor prognosis.
Chemical properties
Technical inquiry about: 3D-HCA04673 Paprotrain
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
